Bruce Cozadd, the retiring CEO of Jazz Pharmaceuticals, has outlined a developing oncology pipeline at the company. Speaking ...

Goldman Sachs raised the firm’s price target on JPMorgan (JPM) to $295 from $273 and keeps a Buy rating on the shares. The firm cites the ...

JPMorgan Chase & Co.'s Chief Executive Jamie Dimon told analysts on Wednesday he plans to stay in the job "for a few more ...

Fresh off a record year for profit and revenue, JPMorgan is facing questions over what CFO Jeremy Barnum admitted was excess capital.

The bank said profit rose 50% to $14 billion in the fourth quarter as noninterest expenses fell 7% from a year earlier.

AstraZeneca says a strong 2024 and stacked pipeline spells potential for further growth in 2025 as the company aims to bring ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Inflation data this week has come in below forecasts. Earnings season is off to a solid start. Is this the medicine the ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

Plus: A stomach flu vaccine, the health impacts of California’s wildfires, lots of nine-figure deals for healthcare startups ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

Joining Amazon’s health benefits marketplace could help drive enrollment in Teladoc’s chronic care management programs, ...